Floriaan Schmidt has received the European Atherosclerosis Society Young Investigator award

The paper assesses the available evidence from both CETP inhibitor trials and from drug target Mendelian randomization (MR) of CETP plasma concentrations, concluding "previous failures of CETP inhibitors are likely related to suboptimal target inhibition (dalcetrapib), off-target effects (torcetrapib), or insufficiently long follow-up (evacetrapib). The present drug target MR analysis, consistent with findings from the anacetrapib trials, anticipates that on-target CETP inhibition decreases CVD risk. MR analyses additionally suggest a reduction in the risk of type 2 diabetes and kidney disease, but an increased risk of age-related macular degeneration." (article link: https://www.nature.com/articles/s41467-021-25703-3) 

Dr Schmidt is a Senior Research Follow with the Institute of Cardiovascular Science at UCL, and holds an Associate Professorship with the Heart and Lungs department at UMC Utrecht in the Netherlands. Floriaan received funding from the British Heart Foundation, the National Institute for Health Research University College London Hospitals Biomedical Research Centre, Servier and Erasmus+.